ES2196092T3 - Composicion antibacteriana liposomica, de baja rigidez. - Google Patents

Composicion antibacteriana liposomica, de baja rigidez.

Info

Publication number
ES2196092T3
ES2196092T3 ES95940928T ES95940928T ES2196092T3 ES 2196092 T3 ES2196092 T3 ES 2196092T3 ES 95940928 T ES95940928 T ES 95940928T ES 95940928 T ES95940928 T ES 95940928T ES 2196092 T3 ES2196092 T3 ES 2196092T3
Authority
ES
Spain
Prior art keywords
liposomic
low rigidity
antibacterial composition
agent
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95940928T
Other languages
English (en)
Inventor
Jacqueline Lagace
Christian Beaulac
Sebastien Clement-Major
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Original Assignee
Universite de Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23430112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2196092(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Universite de Montreal filed Critical Universite de Montreal
Application granted granted Critical
Publication of ES2196092T3 publication Critical patent/ES2196092T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

LA INVENCION SE REFIERE A UNA FORMULACION LIPOSOMAL QUE CONTIENE AL MENOS UNA FORMULACION LIPOSOMAL QUE CONTIENE AL MENOS A UN AGENTE TERAPEUTICO TAL COMO UN ANTIBIOTICO Y A UN METODO PARA TRATAR INFECCIONES BACTERIANAS POR LA ADMINISTRACION DE TAL FORMULACION. SE PREVEN UNA FORMULACION LIPOSOMAL MULTILAMINAR CON POCA RIGIDEZ, LIBRE DE COLESTEROL, QUE INCLUYE UN LIPIDO NEUTRO Y AL MENOS UN AGENTE TERAPEUTICO CON LA QUE LA FORMULACION LIPOSOMAL MEJORA LA PENETRACION DEL AGENTE TERAPEUTICO EN EL INTERIOR DE LA CELULA BACTERIANA. UNA COMBINACION DE LIPIDO PREFERIDA ES DIPALMITOILFOSFATIDILCOLINA (DPPC):DIMIRISTOILFOSFATIDILGLICEROL (DMPG) EN UNA PROPORCION DE 10:1 A 15:1, CON UNA CONCENTRACION TOTAL DE LIPIDO DE ENTRE 5 Y 85 MM.
ES95940928T 1994-12-23 1995-12-22 Composicion antibacteriana liposomica, de baja rigidez. Expired - Lifetime ES2196092T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/363,416 US5662929A (en) 1994-12-23 1994-12-23 Therapeutic liposomal formulation

Publications (1)

Publication Number Publication Date
ES2196092T3 true ES2196092T3 (es) 2003-12-16

Family

ID=23430112

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95940928T Expired - Lifetime ES2196092T3 (es) 1994-12-23 1995-12-22 Composicion antibacteriana liposomica, de baja rigidez.

Country Status (14)

Country Link
US (1) US5662929A (es)
EP (1) EP0806941B1 (es)
JP (1) JP4523078B2 (es)
KR (1) KR100438657B1 (es)
AT (1) ATE235229T1 (es)
AU (1) AU702463B2 (es)
BR (2) BR9510423A (es)
CA (1) CA2206296C (es)
DE (1) DE69530124T2 (es)
DK (1) DK0806941T3 (es)
ES (1) ES2196092T3 (es)
NZ (1) NZ297364A (es)
PT (1) PT806941E (es)
WO (1) WO1996019972A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511477B2 (en) * 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6443949B2 (en) * 1997-03-13 2002-09-03 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6054133A (en) * 1997-07-10 2000-04-25 The Regents Of The University Of California Anti-microbial targeting for intracellular pathogens
US6613352B2 (en) * 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US6365138B1 (en) * 2000-04-07 2002-04-02 The Regents Of The University Of California Compositions for metabolic protection and repair of lips
AU2001275489B2 (en) * 2000-06-16 2005-01-27 Sloan-Kettering Institute For Cancer Research Liposomal encapsulation of chelated actinium-225 and uses thereof
CA2433280C (en) * 2000-12-27 2010-09-21 Salus Pharma, Inc. Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
AU2003225689B2 (en) * 2002-03-05 2009-03-26 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
DE10214983A1 (de) * 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
PT1581236E (pt) * 2002-10-29 2013-12-24 Insmed Inc Libertação prolongada de anti-infecciosos
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
DE10255285A1 (de) * 2002-11-26 2004-06-03 Mcs Micro Carrier Systems Gmbh Selbst formende Phospholipid-Gele
NZ546821A (en) * 2003-10-15 2009-04-30 Pari Pharma Gmbh Liquid preparation containing tobramycin
US20050214224A1 (en) * 2003-11-04 2005-09-29 Nektar Therapeutics Lipid formulations for spontaneous drug encapsulation
EP3067046B1 (en) * 2005-12-08 2020-03-25 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
DE102009031274A1 (de) 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
EP2731590B1 (en) 2011-07-13 2018-05-23 The Foundry, LLC Methods and apparatus for delivering a therapeutic agent to nasopharyngeal mucosa targets
SI2852391T1 (sl) 2012-05-21 2022-04-29 Insmed Incorporated Sistemi za obravnavo pljučnih infekcij
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
DK3466432T3 (da) 2014-05-15 2020-09-28 Insmed Inc Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
AU2015301234A1 (en) 2014-08-04 2017-06-15 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into lipid vesicles
ES2574615B1 (es) * 2014-12-19 2017-07-24 Biopraxis Research Aie Nanopartícula lipídica de tobramicina
CN111372603A (zh) * 2017-10-02 2020-07-03 阿瑞迪思医药品股份有限责任公司 针对铜绿假单胞菌感染的组合物和方法
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
CN117017999A (zh) * 2023-09-20 2023-11-10 四川大学 一种夫西地酸磷脂复合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4981692A (en) * 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
US4952405A (en) * 1988-10-20 1990-08-28 Liposome Technology, Inc. Method of treating M. avium infection
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
PT100486B (pt) * 1992-05-14 1999-07-30 Ineti Inst Nac Engenh E Tecnol Aminoglucosidos lipossomais com altas eficacia de encapsulacao e actividade terapeutica, nomeadamente a netilmicina, e processo para a sua preparcao
WO1994012155A1 (en) * 1992-12-02 1994-06-09 Vestar, Inc. Antibiotic formulation and process

Also Published As

Publication number Publication date
EP0806941B1 (en) 2003-03-26
KR980700062A (ko) 1998-03-30
CA2206296C (en) 2007-05-22
JPH10511363A (ja) 1998-11-04
BRPI9510423B8 (pt) 2019-11-05
US5662929A (en) 1997-09-02
JP4523078B2 (ja) 2010-08-11
AU702463B2 (en) 1999-02-25
WO1996019972A1 (en) 1996-07-04
DE69530124D1 (de) 2003-04-30
BR9510423A (pt) 2003-01-07
CA2206296A1 (en) 1996-07-04
DK0806941T3 (da) 2003-07-21
NZ297364A (en) 2000-01-28
AU4251096A (en) 1996-07-19
ATE235229T1 (de) 2003-04-15
KR100438657B1 (ko) 2004-08-18
MX9704679A (es) 1998-07-31
DE69530124T2 (de) 2004-02-05
EP0806941A1 (en) 1997-11-19
PT806941E (pt) 2003-08-29

Similar Documents

Publication Publication Date Title
ES2196092T3 (es) Composicion antibacteriana liposomica, de baja rigidez.
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
ES2188652T3 (es) Sistema de direccionado de farmacos, metodos de fabricacion y uso del mismo.
AU2526095A (en) Transdermal device for administration through de-epithelialized skin
DE60134855D1 (de) Orale zubereitungen, die antimikrobielle wirkstoffe enthalten zur prävention von systemischen erkrankungen
EA199900553A1 (ru) Чрескожная терапевтическая система
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
NZ510690A (en) Methods for administration of antibiotics
ATE316794T1 (de) Pharmazeutische zusammensetzungen enthaltend lysostaphin allein oder in kombination mit einem antibiotikum zur behandlung von staphylokokkeninfektionen
BRPI9915480B8 (pt) azalídeos de 13 membros, composições farmacêuticas compreendendo os mesmos, método para sua preparação bem como seus usos.
GEP20002332B (en) Cefalosporin Derivatives
AU3902299A (en) Methods of treating microbial infection and therapeutic formulations therefor
PT1272199E (pt) Terapias de combinacao com actividade de lesao vascular
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituált ketolidszármazékok
HUP0004579A2 (hu) Antibakteriális hatású, a 3'-N-pozícióban módosított szerkezetű 6-0-szubsztituált-eritromicin-ketolid-származékok és ezeket tartalmazó gyógyszerkészítmények
KR950026524A (ko) 피부질환 치료용 의약조성물
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
WO2000012049A3 (en) A method for the treatment of staphylococcal disease
ATE258375T1 (de) Behandlungen von der foulbroodbienenkrankheit
GR3004655T3 (es)
DE69941459D1 (de) Verfahren zur herstellung von essbaren zusammenstellungen mit antibakteriellen wirkstoffen
Olay et al. Experimental Staphylococcus aureus osteomyelitis treated with fosfomycin and cephazolin: Single and combined therapy.
ES2086518T3 (es) Compuesto farmaceutico con accion cicatrizante.
WO1992018090A3 (en) Antimicrobial oral compositions